Wealthfront Advisers LLC Invests $209,000 in Twist Bioscience Co. (NASDAQ:TWST)

Wealthfront Advisers LLC acquired a new position in Twist Bioscience Co. (NASDAQ:TWST) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,113 shares of the company’s stock, valued at approximately $209,000.

Other institutional investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Twist Bioscience in the 3rd quarter worth $34,000. Van ECK Associates Corp boosted its position in shares of Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares in the last quarter. US Bancorp DE boosted its position in shares of Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock worth $67,000 after purchasing an additional 601 shares in the last quarter. Beaird Harris Wealth Management LLC acquired a new stake in shares of Twist Bioscience in the 3rd quarter worth $95,000. Finally, KBC Group NV boosted its position in shares of Twist Bioscience by 71.4% in the 4th quarter. KBC Group NV now owns 2,942 shares of the company’s stock worth $137,000 after purchasing an additional 1,226 shares in the last quarter.

Insider Activity at Twist Bioscience

In related news, CEO Emily M. Leproust sold 1,654 shares of Twist Bioscience stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $44.90, for a total value of $74,264.60. Following the completion of the transaction, the chief executive officer now owns 673,064 shares in the company, valued at $30,220,573.60. The trade was a 0.25 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dennis Cho sold 806 shares of Twist Bioscience stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $39,776.10. Following the completion of the transaction, the insider now owns 112,221 shares of the company’s stock, valued at approximately $5,538,106.35. This represents a 0.71 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 33,712 shares of company stock worth $1,597,720 in the last 90 days. Corporate insiders own 3.01% of the company’s stock.

Twist Bioscience Stock Performance

NASDAQ TWST opened at $42.34 on Tuesday. The stock has a 50-day simple moving average of $45.64 and a two-hundred day simple moving average of $45.27. The firm has a market capitalization of $2.53 billion, a P/E ratio of -12.53 and a beta of 2.15. Twist Bioscience Co. has a fifty-two week low of $27.41 and a fifty-two week high of $60.90. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.62 and a current ratio of 4.96.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.62) by $0.09. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The business had revenue of $88.70 million during the quarter, compared to analyst estimates of $86.96 million. During the same quarter last year, the business posted ($0.75) EPS. The company’s revenue was up 24.1% on a year-over-year basis. On average, equities analysts forecast that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the company. TD Cowen reissued a “buy” rating and issued a $58.00 price objective on shares of Twist Bioscience in a research report on Tuesday, November 26th. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Scotiabank reaffirmed an “outperform” rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Barclays set a $58.00 price target on Twist Bioscience and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, Robert W. Baird lifted their price target on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $54.40.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.